Literature DB >> 29338112

Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

Steven G Chrysant1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29338112      PMCID： PMC8030897          DOI： 10.1111/jch.13169

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  28 in total

1.  Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Authors:  Luis Miguel Ruilope; Andrej Dukat; Michael Böhm; Yves Lacourcière; Jianjian Gong; Martin P Lefkowitz
Journal:  Lancet       Date:  2010-03-16       Impact factor: 79.321

2.  Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Kazuomi Kario; Ningling Sun; Fu-Tien Chiang; Ouppatham Supasyndh; Sang Hong Baek; Akiko Inubushi-Molessa; Ying Zhang; Hiromi Gotou; Martin Lefkowitz; Jack Zhang
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

3.  Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.

Authors:  Scott D Solomon; Brian Claggett; John J V McMurray; Adrian F Hernandez; Gregg C Fonarow
Journal:  Eur J Heart Fail       Date:  2016-06-30       Impact factor: 15.534

4.  Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.

Authors:  Bryan Williams; John R Cockcroft; Kazuomi Kario; Dion H Zappe; Patrick C Brunel; Qian Wang; Weinong Guo
Journal:  Hypertension       Date:  2017-01-16       Impact factor: 10.190

5.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

6.  Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study.

Authors:  Riccardo Pini; M Chiara Cavallini; Vittorio Palmieri; Niccolò Marchionni; Mauro Di Bari; Richard B Devereux; Giulio Masotti; Mary J Roman
Journal:  J Am Coll Cardiol       Date:  2008-06-24       Impact factor: 24.094

7.  Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Authors:  Hisham Qosa; Bilal S Abuasal; Ignacio A Romero; Babette Weksler; Pierre-Oliver Couraud; Jeffrey N Keller; Amal Kaddoumi
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

8.  Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension.

Authors:  J Jordan; R Stinkens; T Jax; S Engeli; E E Blaak; M May; B Havekes; C Schindler; D Albrecht; P Pal; T Heise; G H Goossens; T H Langenickel
Journal:  Clin Pharmacol Ther       Date:  2016-11-17       Impact factor: 6.875

Review 9.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

Review 10.  From ARB to ARNI in Cardiovascular Control.

Authors:  Estrellita Uijl; Lodi C W Roksnoer; Ewout J Hoorn; A H Jan Danser
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369
View more
  3 in total

1.  Antisense regulation of atrial natriuretic peptide expression.

Authors:  Selvi Celik; Mardjaneh Karbalaei Sadegh; Michael Morley; Carolina Roselli; Patrick T Ellinor; Thomas Cappola; J Gustav Smith; Olof Gidlöf
Journal:  JCI Insight       Date:  2019-10-03

2.  Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

Authors:  Steven G Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-16       Impact factor: 3.738

Review 3.  Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe.

Authors:  Donna S-H Lin; Tzung-Dau Wang; Peera Buranakitjaroen; Chen-Huan Chen; Hao-Min Cheng; Yook Chin Chia; Apichard Sukonthasarn; Jam Chin Tay; Boon Wee Teo; Yuda Turana; Ji-Guang Wang; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-12-11       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.